Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | BLM | P54132 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.30 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.30 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17749257 | 1.00 | DPP4 (0.46) | DPP4CYP2C19CYP2D6LMNABLM | |
| SCHEMBL15635036 | 1.00 | DPP4 (0.46) | DPP4CYP2C19CYP2D6LMNABLM | |
| SCHEMBL21295300 | 1.00 | DPP4 (0.46) | DPP4CYP2C19CYP2D6LMNABLM | |
| SCHEMBL17749319 | 1.00 | DPP4 (0.46) | DPP4CYP2C19CYP2D6LMNABLM | |
| Hydrochloric Acid SCHEMBL25410714 | 0.98 | DPP4 (0.45) | DPP4CYP2C19CYP2D6LMNABLM | |
| SCHEMBL15268220 | 0.83 | DPP4 (0.48) | DPP4CYP2C19CYP2D6LMNABLM | |
| SCHEMBL17460897 | 0.81 | DPP4 (0.45) | DPP4 | |
| SCHEMBL17460898 | 0.81 | DPP4 (0.45) | DPP4 | |
| SCHEMBL14672272 | 0.80 | CYP2C19 (0.44) | DPP4CYP2C19CYP2D6LMNABLM | |
| SCHEMBL31435479 | 0.76 | DPP4 (0.42) | DPP4KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170348266-A1 | INHIBITION OF PROLINE CATABOLISM FOR THE TREATMENT OF CANCER AND OTHER THERAPEUTIC APPLICATIONS | BUCK INSTITUTE FOR RESEARCH ON AGING | 2017-12-07 | — | — | US | claimed |
| WO-2016077632-A2 | INHIBITION OF PROLINE CATABOLISM FOR THE TREATMENT OF CANCER AND OTHER THERAPEUTIC APPLICATIONS | BUCK INSTITUTE FOR RESEARCH ON AGING (US) | 2016-05-19 | — | — | WO | claimed |
| US-20240124522-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2024-04-18 | — | — | US | disclosed |
| US-11667675-B2 | MASP inhibitory compounds and uses thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-06 | — | — | US | disclosed |
| US-20210246166-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2021-08-12 | — | — | US | disclosed |
| WO-2020225095-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2020-11-12 | — | — | WO | disclosed |
| US-20170348266-A1 | INHIBITION OF PROLINE CATABOLISM FOR THE TREATMENT OF CANCER AND OTHER THERAPEUTIC APPLICATIONS | BUCK INSTITUTE FOR RESEARCH ON AGING | 2017-12-07 | — | — | US | disclosed |
| WO-2016077632-A2 | INHIBITION OF PROLINE CATABOLISM FOR THE TREATMENT OF CANCER AND OTHER THERAPEUTIC APPLICATIONS | BUCK INSTITUTE FOR RESEARCH ON AGING (US) | 2016-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170348266-A1 | INHIBITION OF PROLINE CATABOLISM FOR THE TREATMENT OF CANCER AND OTHER THERAPEUTIC APPLICATIONS | GLUL, GLS2, PHGDH | DPP4 462/4885CYP2C19 1521/4885CYP2D6 1097/4885 |
| US-11667675-B2 | MASP inhibitory compounds and uses thereof | MASP2, SERPINB1, SPINT2 | DPP4 109/4885CYP2C19 4587/4885CYP2D6 4444/4885 |
| US-20240124522-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | MASP2, SERPINB1, SPINT2 | DPP4 109/4885CYP2C19 4587/4885CYP2D6 4444/4885 |
| US-20210246166-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | MASP2, SERPINB1, SPINT2 | DPP4 109/4885CYP2C19 4587/4885CYP2D6 4444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.